Core Viewpoint - FibroBiologics, Inc. has successfully closed the third $5 million tranche of a Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors, allowing the company to raise up to $25 million over two years for its therapeutic development efforts [1][2]. Financing Details - The SEPA allows FibroBiologics to sell up to $25 million in common stock to Yorkville over two years, with the first three tranches totaling $15 million being advanced in equal parts of $5 million each [2]. - The third tranche of $5 million was funded after the effectiveness of a registration statement and shareholder approval, complying with Nasdaq rules [2]. Use of Proceeds - The net proceeds from this financing are intended for general corporate purposes, including funding research and development programs and supporting an upcoming Phase 1/2 clinical trial for diabetic foot ulcers expected to start in the second half of 2025 [3]. Company Overview - FibroBiologics is a clinical-stage biotechnology company based in Houston, focusing on developing therapeutics and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials [7][8]. - The company holds over 275 patents issued and pending, covering various clinical pathways such as wound healing, multiple sclerosis, and cancer [8].

HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics, will present on FibroBiologics' unique fibroblast cell-based approach for the potential treatment of chronic di ...